Galderma To Present Five Abstracts in Support of Novel Aesthetics Solutions and Pipeline at ASDS 2020 Annual Meeting
Galderma today announced the presentation of data from clinical trials of its aesthetic solutions and pipeline in five abstracts at the virtual American Society for Dermatologic Surgery (ASDS) 2020 Annual Meeting. The company also announced that it has completed patient enrollment in several clinical trials supporting a Phase 3 program of relabotulinumtoxinA (QM1114), its proprietary novel, ready-to-use, liquid formulation of investigational botulinum toxin, for the treatment of glabellar lines and lateral canthal lines. The Phase 3 program, called READY (RElabotulinumtoxin Aesthetic Development studY), enrolled over 1,900 patients across 60 sites in the United States and Canada in four clinical trials – three multi-center, randomized, double-blind, placebo-controlled studies and one long-term open-label study.
RelabotulinumtoxinA clinical trials will evaluate rapid onset, long duration, and additional patient measures as part of the large clinical program for this next generation botulinum toxin. The liquid formulation will be ready to use upon arrival and will not require in-office reconstitution before administration, it will reduce preparation time, and has the potential to increase accuracy and improve patient outcomes, in contrast with current treatments that require reconstitution by clinicians before administration. Derived from Galderma’s proprietary strain of Clostridium botulinum bacteria and created using an animal-origin free process, relabotulinumtoxinA will be manufactured in Galderma’s new state-of-the-art Center of Excellence in Aesthetics in Uppsala, Sweden.
“Our patient-first approach to aesthetics innovation has resulted in seven FDA approvals over the last six years. Based on the success of the latest outcomes we’ve shared today, and our continued work to bring patients safe and long-lasting results, we also expect to receive six more approvals in the next three years,” said Dr. Flemming Ornskov, MD, MPH, Chief Executive Officer, Galderma. “The launch of Restylane® Kysse earlier this year has shown the strong demand for new aesthetic solutions to improve the patient and provider experience throughout 2020. Our robust Phase 3 and Phase 4 clinical programs have helped propel the launch of Restylane® Kysse, and the data presented today underscores our relentless focus on meeting the needs of our customers.”
Galderma’s Data Presentations at ASDS 2020
During the ASDS meeting, Galderma will present clinical research findings across its neurotoxin and dermal fillers portfolio. The company’s oral and poster presentations will highlight results from the DREAM (Dysport Real-world Evaluation and Measured satisfaction) study of Dysport® (abobotulinumtoxinA) for Injection*, which demonstrated high levels of patient satisfaction and natural-looking results with only two treatments per year1. Additionally, Phase 3 clinical research showed that Restylane® Defyne was effective for correction of chin retrusion and was associated with a high degree of patient satisfaction, and Restylane® Kysse was shown to be effective for lip augmentation over a 48-week treatment period with a high degree of patient satisfaction. In a Phase 4 study of Restylane® Kysse, both subjects and their partners were satisfied with the subjects’ lips after treatment.2,3
“The results of the DREAM study showing the long duration of Dysport and high patient satisfaction with treatments given twice a year are especially important as it’s the first toxin to showcase this extended patient satisfaction benefit,”1 said Dr. Carolyn Jacob, MD, FAAD, Founder and Medical Director of Chicago Cosmetic Surgery and Dermatology and an investigator for the DREAM study. “The study data showing that 95% of patients were satisfied or highly satisfied with the aesthetic results of treating the lines between their eyebrows every six months for a year with Dysport should give patients and aesthetic specialists confidence in this treatment regimen.”1
Details about Galderma’s presentations are as follows:
- A randomized, no-treatment controlled, evaluator-blinded, multi-center phase 3 study to evaluate the effectiveness and safety of HARD in the chin for augmentation and correction of chin retrusion – Dr. Anne Chapas (Oral Abstract: Friday October 9, 9:09-9:12 a.m.)
- A randomized, controlled, evaluator-blinded, multicenter study to evaluate the effectiveness and safety of HAkys versus a control in augmentation of soft tissue fullness of the lip – Dr. Sue Ellen Cox (Oral Abstract: Friday October 9, 9:03-9:06 a.m.)
- Post marketing study to evaluate lip enhancement, naturalness, and satisfaction of both subject and partner after treatment with HARK – Dr. Vince Bertucci (Oral Abstracts #5: Saturday, October 10, 11:30-11:33 a.m.)
- Subjects are highly satisfied with two treatments of abobotulinumtoxinA a year: results from multi-center, year-long, longitudinal study – Dr. Ava Shamban (e-poster)
- A randomized, evaluator-blinded, multi-center phase 3 study to evaluate safety and effectiveness of a biostimulatory poly-l-lactic acid injectable implant after changes in reconstitution – Dr. Melanie Palm (e-poster)
About Galderma’s collaboration with Ipsen
Dysport® (abobotulinumtoxinA) is a prescription injection for temporary improvement in the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years of age. Dysport® is also marketed as Azzalure® in the EU for the treatment of glabellar lines with more than 40 million treatments in the EU and U.S. combined and with approvals in 74 countries.
Dysport® is manufactured by Ipsen, a global specialty-driven pharmaceutical company. Since 2009, Galderma and Ipsen have had a strategic partnership under which Galderma has promoted and distributed Ipsen’s botulinum toxin type A products in aesthetic indications. The Ipsen-Galderma strategic partnership now covers China, the United States, the European Union, Australia, South Korea, Canada, Brazil, Argentina and certain other countries. Ipsen continues to promote Dysport® within certain neuromuscular disorder indications in countries around the world. For more information on Ipsen, visit www.ipsen.com.
Galderma, the world's largest independent global dermatology company, was created in 1981 and is now present in over 100 countries with an extensive product portfolio of prescription medicines, aesthetic solutions and consumer care products. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin. For more information, please visit http://www.galderma.com/.
Follow Galderma on Instagram at @GaldermaAesthetics
# # #
To learn more about serious but rare side effects and full Important Safety Information, visit www.RestylaneUSA.com.
The Dysport trademark is used under license. All trademarks are the property of their respective owners.
©2020 Galderma All Rights Reserved.
1 Data on file. Study 43USD1802. Galderma, Fort Worth, TX, 2020.
2 Galderma. Clinical Study Report: Post Marketing Study to Evaluate Lip Enhancement, Naturalness and Partner/Subject Satisfaction after Treatment with Restylane® Kysse N/A Restylane Kysse 2020; 29.
3 FDA. Restylane Kysse Instructions for Use (IFU) N/A Restylane Kysse 2020.
Investor and media relations
Christian Marcoux, M.Sc.
Chief Communications Officer
+41 21 642 71 99
Isabella Laihorinne Smedh
PR & Communications, Galderma
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ergomotion Announces Opening of First Manufacturing Facility in North America29.10.2020 22:28:00 CET | Press release
Ergomotion, part of the Keeson Technology Group and the largest manufacturer of adjustable bases worldwide, will open a 250,000 square foot manufacturing facility in Ciudad Juárez, Chihuahua, the company’s first assembly plant in North America. The expansion was fueled by the decision to increase product capabilities, oversee manufacturing functions, and ultimately to stay closer to Ergomotion’s customer base in the United States. “We see a prime opportunity with the North America expansion to enhance the customer service experience in the U.S.,” says Johnny Griggs, Chief Operating Officer at Ergomotion. “Our goal is to provide our partners with world class manufacturing and supply chain and to help grow and strengthen their business. We’re excited to partner with Ciudad Juárez to expand our manufacturing capabilities and make this project viable and successful.” Ergomotion is making a significant investment that will allow for the creation of 400 jobs, within the local economy. The Ju
IDEMIA Launches Converged Card to Enable Financial Inclusion with Identity and Payment Card Solution29.10.2020 17:45:00 CET | Press release
IDEMIA, a global leader in identity and security solutions and the number one provider of driver’s licenses in the U.S., today announced the development of a Converged Card solution in partnership with Mastercard, allowing cardholders to safely and securely shop for everyday essentials. The solution will help bring more people into the formal economy in the U.S. who currently have limited or no access to financial services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201029005916/en/ IDEMIA Launches Converged Card to Enable Financial Inclusion with Identity and Payment Card Solution (Photo: Business Wire) Converged Card1 is a state-issued driver’s license or identification with a payment credential. This card or digital application will support state-subsidized programs, including unemployment benefits, housing and utility assistance, and tax refunds, allowing the government to automatically reach people that need funding
Airship Named a Leader in the 2020 Gartner Magic Quadrant for Mobile Marketing Platforms29.10.2020 16:34:00 CET | Press release
Customer engagement companyAirship today announced that it has been named a Leader by Gartner, Inc. in its 2020 Magic Quadrant for Mobile Marketing Platforms.1 Among 13 vendors evaluated, Airship was positioned highest in its ability to execute and furthest to the right for its completeness of vision for the second consecutive year. A complimentary copy of the report is available from Airship. “Airship’s long held global leadership in customer engagement is experiencing dramatic acceleration, as new mobile-first capabilities like Airship Journeys make it much simpler and more effective to grow customer lifetime value in the omnichannel era. I believe Airship’s latest innovations, as well as expansions to experimentation and commerce, are already recognized as major beneficial differentiators in comprehensive evaluations like Gartner’s Magic Quadrant and Critical Capabilities reports,” said Brett Caine, CEO and president, Airship. “As mobile becomes increasingly vital for brands and the
myPOS Turns Smartphones Into POS Terminals29.10.2020 16:02:00 CET | Press release
Business professionals can now take card payments directly on their Android phone with the new Soft POS solution myPOS Glass by the European fintech provider myPOS (www.mypos.com). The innovative mobile app enables payments with contactless cards and smart accessories directly on a mobile Android phone. The accepted payments are deposited immediately in the merchant's free e-money account thanks to the instant settlement feature that myPOS offers at no extra cost for its clients. The Soft POS solution can be used on Android devices that have an NFC (Near Field Communication) chip, which is present in most current smartphones. It does not require additional hardware or cables to turn the phone into a payment terminal. myPOS Glass accepts all types of credit, debit and prepaid Mastercard and Visa cards, as well as wallets like Apple Pay, Google Pay and Samsung Pay. The application meets all industry standards for data protection and security. It ensures that the cardholder's data is not
Andersen Global Extends Coverage in St. Kitts and Nevis29.10.2020 14:30:00 CET | Press release
Andersen Global continues its Caribbean expansion through a Collaboration Agreement with full-service accounting firm Lanns-Monish & Associates, adding dimension to the organization’s presence in St. Kitts and Nevis. Founded in 1991, the Basseterre-based firm is led by founder and Office Managing Director Marcella Lanns-Monish. The team of ten professionals provides tax and accounting services to domestic and international clients, including business advisory, corporate restructuring, tax compliance, payroll and risk advisory. In addition, they provide services to a variety of industries, including hospitality, tourism, manufacturing and the public sector. “The dedication and stewardship of our team to provide clients with best-in-class service has helped us become leaders in our practice areas,” said Marcella. “This collaboration will allow us to take our client service to the next level and expand our reach more broadly. We are excited to work in tandem with Andersen’s collaborating
Conviva’s Latest Streaming Data Shows Advertisers Beginning to Reemerge; Rise of Smart TVs Slows Growth for Connected TV Devices29.10.2020 14:00:00 CET | Press release
Conviva, the leader in global streaming media intelligence, released its quarterly State of Streaming report for Q3 2020 today, showing a 57% year over year increase in overall viewing time, continuing the trend of multiple quarters of strong streaming growth. The report also uncovered new streaming trends including the long-awaited return of advertisers and the increasing battle between smart TVs and connected TV devices such as Roku. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201029005174/en/ Conviva's State of Streaming - Q3 2020 (Graphic: Business Wire) “Streaming has exploded in the past year as illustrated by content like the NFL which saw 41% growth on streaming and remained relatively flat on linear TV,” said Bill Demas, CEO, Conviva. “As a result, we are seeing more investment in streaming services, advertisers shifting to streaming platforms and consumers adopting streaming-enabled devices and TVs at a rapid pa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom